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Abstract 
Background: Post- operative prosthetic joint infection (PJI) is the most common cause of failure of 
total joint arthroplasty, requiring revision surgery, but a gold standard for the diagnosis and the 
consequent treatment of PIJ is still lacking. Among the scenario of infections diagnosis, an 
emerging molecule is Presepsin, the soluble fraction of CD14, recently described as a powerful 
diagnostic tool, not only to detect sepsis but also to discriminate different grade of sepsis severity.  
Question / purpose: We asked:1) is Presepsin a good diagnostic marker for PJI? 2) Does Presepsin 
correlate with other emerging infection markers such as TREM-1, CD-163, SuPAR, OPN and MMP-
9, sTLR2 and CCL2 and IL-6?3) Is Presepsin a good prognostic marker of PJI? 
Methods: The population of 100 selected patients undergoing prosthesis revision was enrolled and 
subdivided into two groups: 48 patients having bacterial infection and 52 patients with no 
infection, undergoing aseptic loosening of the implant. CRP was measured using 
immunoturbidimetry on an automated biochemical analyzer (Olympus CRP-Latex assay, Central 
Valley, PA, CA, USA) Serum IL-6, TREM-1, CCL2, MMP-9, CD-163 and OPN were measured using an 
ELISA sandwich Quantikine Assay, while TLR2 was measured using an ELISA Duo Set Assay, 
according to manufacturer protocol (R&D System, Minneapolis, MN, USA). SuPAR was measured 
by SuPARnostic ELISA Assay, according to manufacturer protocol (Virogates, Denmark). Presepsin 
plasmatic levels were measured by Presepsin/ PATHFAST according to manufacturers’ protocol 
(Mitsubishi Chemical). PATHFAST Presepsin is a chemioluminescent enzyme immune assay (CLEIA) 
for the quantitative measurement of Presepsin concentration in whole blood or plasma. 
Results: Presepsin has a greater diagnostic value than CRP and IL-6 in the diagnosis of PJI, as 
assessed by ROC CURVE analysis. OPN, CCL2, TLR2 and SuPAR displayed good diagnostic values in 
PJI, while CD163, TREM-1 and MMP-9 displayed very low diagnostic potential. Presepsin, as well as 
OPN, CCL2, SuPAR and TLR2, displayed a significant decrease at the increasing time of recovery 
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after surgery in PJI patients, while it remains unaltered and significantly lower (p<0.0001) in the 
patients undergone to revision surgery for aseptic loosening of the implant. These results clearly 
indicate that Presepsin have a good prognostic value, because it decreases gradually as the 
inflammatory process in response to the prosthetic infection is resolved.  
Conclusions: Taken together, these results indicate that Presepsin can be considered a useful tool 
for the diagnosis and clinical monitoring of PJI, and it can also be supported by a panel of new 
inflammatory makers involved in monocyte/macrophage mediated inflammatory response such as 
OPN, CCL2, TLR2 and SuPAR. 
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1. Introduction: Definition of Prosthetic joint infection (PJI) 
Pathogen infection is one of the main adverse events of surgical procedures, which can lead to an 
excess of systemic inflammatory response and sepsis, causing multi organ failure and septic shock. 
In particular, in orthopedic field, one of the most challenging complication associated with surgical 
procedures is periprosthetic joint infection (PJI). 
PIJ is the most common cause of failure of total joint arthroplasty, requiring revision surgery. 
PJI is mainly due to Gram-positive bacteria, in particular, Staphylococcus Aureus, and more rarely 
by Gram-negative bacteria such as Pseudomonas Aeruginosa. [1,2] 
A short percentage of hip (1.7% - 3.2%) and knee (2.5%-5.6%) prosthetic joint replacement surgery 
undergoes prosthetic infection, therefore an appropriate recognition and clinical approach are 
essential to preserve or re-establish adequate function and limit excess morbidity. 
The reasons of the failure include aseptic loosening at the bone-cement surface, periprosthetic 
fracture, fracture of the prosthetic device itself, wear, implant malposition, dislocation-
instabilities, hard material and Prosthetic Joint Infection. 
Prosthetic joint infection (PJI), also known as periprosthetic infection, is defined as infection 
involving the articulation of the prosthesis and adjoining tissue. Advances in the understanding of 
the epidemiology, diagnosis, management and prevention of PJI over the past decades have led to 
an improvement in the resolution of this challenging infection. 
It’s extremely important to identify periprosthetic joint infection as early as possible, in order to 
start promptly antibiotic treatment and, in worse case, program a surgical revision arthroplasty. 
Different definition of PJI have been proposed so far, but at the moment there is not a uniform 
definition. The diagnosis of PJI is currently based on several criteria provided by Musculoskeletal 
Infection Society (MSIS), in 2011.[1,3]
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1.1   PJI Diagnosis 
The diagnosis of PJI is difficult because the clinical presentation is various in the patients and at the 
moment a single gold standard able to identify Periprosthetic Joint Infection is still lacking. 
Currently the diagnosis of PJI is based on proposed criteria consensus by Musculoskeletal Infection 
Society (2011) and Philadelphia accord on the PJI determination (2013). 
PJI exist when the following major criteria is present: 
“isolation of pathogens by culture from two or more separate tissue or fluid samples obtained from 
the affected prosthetic joint” 
Or when four of the sequent minor criteria are present: 
 
1. Elevated serum erythrocyte sedimentation rate (ESR), 
2. Elevate serum C-reactive protein (CRP) concentration, 
3. Elevated synovial white Blood Cells (WBC) count, 
4. Elevated synovial neutrophil percentage (PMN%), 
5. Purulence in the affected joint, 
6. Higher than five neutrophils for high-power field in five high-power fields analyse from 
histologic section of periprosthetic tissue at ×400 magnification. [3,4] 
 
Currently the PJI identification is based on: clinical manifestation, microbiological test, 
histopathological analysis and imagining tools, but this types of investigation are invasive tests for 
the patients.  
Moreover, microbiological culture tests often provide false negative results. 
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In addition to these inclusion criteria, serum parameters can also be evaluated, in particular 
inflammatory markers (Procalcitonin, C reactive protein and IL-6).  
Recent evidences indicated that IL-6 and CRP are useful in the diagnosis of PJI, while Procalcitonin 
had not a great diagnostic value in PJI. [5] 
For this reason, in order to optimize the diagnostic process, infection biomarkers with fast 
response and high sensitivity and specificity for PJI Infection are needed.  
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2. Ideal Biomarker in PJI Diagnosis 
Currently, a large number of test are available for PIJ diagnosis, ranging from hematological 
markers of infection and inflammation, intraoperative culture and histology analysis, and many 
can be used in combination. Nevertheless, there is still a lack of gold standard for the early 
diagnosis and the consequent treatment of PIJ. [6] 
The assay used to measure an ideal infection marker should: 
 Be reliable and reproducible in different settings, 
 Provide an information from a different type of sample that can be obtained easily, 
 Provide rapid information, 
 Identify presence or absence of sepsis, 
 Aid in risk stratification and/or identify those patients that will benefit from a specific 
therapeutic intervention, 
 Monitor the response to an intervention and/or aid in titrating the intervention. 
 
But: 
 No single biomarker can assist the physician at the bedside in sepsis detection or risk 
stratification, 
 Biomarker panels (including RNA’s) may be more discriminant, 
 Rapid point-of-care tests are needed to implement the use of biomarker in clinical practice, 
To date in the clinical practice there isn’t a biomarker panel able to identify PJI infection as early as 
possible. 
For these reason my PhD thesis was focused on to investigate the diagnostic and prognostic 
potential of emerging biomarkers involved in the inflammatory response, such as the new 
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emerging biomarker Presepsin, in particular investigating the inflammatory mediators involved 
such as the chemokine CCL2 and the inflammatory cytokine, IL-6. 
The diagnostic and prognostic value of Presepsin in PIJ was also investigated correlating Presepsin 
values with other emerging infection marker such as TREM-1, CD-163, SuPAR, OPN, TLR2 and 
MMP-9 which could be involved in the progression of PJI. 
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2.1 Biomarkers currently used in PJI Diagnosis  
In this context, a previous study of our group investigated the possibility to improve the diagnosis 
of PIJ, investigating role of Procalcitonin, C reactive protein and IL-6 as markers of post-operative 
orthopedics joint prosthesis infection, indicating that IL-6 and CRP were useful in the 
differentiation between patient with or without post-operative PIJ, while Procalcitonin had not a 
great diagnostic value in this case. Therefore, there is still need to improve the diagnostic tools for 
the early detection of PJI. [5] 
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2.1.1 C Reactive Protein (CRP) 
C reactive protein is a pentameric protein produced by the liver and it is found in plasma. 
it is an acute-phase protein and its plasmatic level increase when there is an inflammatory 
process. 
CRP is expressed on the surface of dead or dying cells and its increases follows interleukin-6 
secretion by macrophages and T cells. CRP plays a role in innate immunity as an early defense 
system against infections. When CRP is expressed, there is an activation of the complement 
system, promoting the phagocytosis by macrophages, which remove necrotic and apoptotic cells 
and bacteria. In particular CRP binds to phosphocholine on micro-organisms, in order to stimulate 
complement binding to bacteria and enhancing phagocytosis by macrophages (opsonin-mediated 
phagocytosis), which express CRP receptor.  
This acute phase response occurs as a result of an increase of IL-6, which is produced by 
macrophages and adipocytes in response to a wide range of acute and chronic inflammatory 
conditions such as bacterial, viral, or fungal infections, rheumatic and other inflammatory 
diseases, malignancy, tissue injury and necrosis. [7] 
These conditions lead to the production of interleukin-6 and other cytokines that trigger the 
synthesis of CRP and fibrinogen by the liver. 
The cut off value for the clinical diagnosis of inflammatory is 1 mg/dL. [7,8] 
CRP increases within two hours of the onset of inflammation, up to a 50,000-fold, and peaks at 48 
hours. Its half-life of 18 hours is constant, therefore its level is determined by the rate of 
production and hence by the severity of the precipitating cause. CRP is thus a marker for 
inflammation. 
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CRP plasma level has not a strong specificity because in patients with chronic inflammation, 
metabolic syndrome, smoking and obese subjects the value of CRP may be a little bit higher that 1 
mg/dL. 
In plasma CRP as diagnostic marker displays the following features: 
 Sensibility of 0,71 
 Specificity of 0.97 
 Accuracy of 0.88 
 Positive Predictive Value of 0.93 
 Negative predictive Value of 0.87 
 Likelihood ratio for positive results 23.6 
In prosthetic joint infection patients, the levels of CRP are lower compared to the higher value 
measured in inflammatory condition, where the values are greater than 10 mg/dl. For this reason, 
even if there is a statistical significative increase in PJI patients compared to not infected ones, CRP 
is not sufficient to identify PJI and it cannot be considered a useful tool for PJI diagnosis. [8,9]   
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2.1.2 PROCALCITONIN (PCT) 
Procalcitonin (PCT) is a peptide of the hormone calcitonin, involved with calcium homeostasis. PCT 
is produced form thyroid cells and neuroendocrine cells. 
Blood level of procalcitonin in healthy individuals is lower than the cut off value of <50 pg/mL. 
The level of PCT increase over the cut off value in response to a pro-inflammatory stimulus, 
especially of bacterial origin. There isn’t a statistically significantly increase of PCT serum levels in 
viral or non-infectious inflammations. Therefore, procalcitonin can be considered specific for 
bacterial infection. In serum, PCT has a half-life of 25 to 30 hours. [7,10] 
PCT is a new generation marker showing properties different from other inflammatory markers 
currently used: 
- PCT is selectively produced in case of bacterial infection, sepsis and multi organ dysfunction 
syndrome, 
- PCT cut off is very low (50 pg/ml), therefore increasing PCT assay sensitivity  
- PCT plasma levels is very high in severe bacterial infection (100 ng/ml). 
Procalcitonin blood concentration is used as a marker of bacterial infection and in case of severe 
sepsis. Compared to other markers such as IL- 6, C-Reactive Protein and TNF-alpha, procalcitonin 
shows highest levels of sensitivity (85%) and specificity (91%) in the differential diagnosis between 
of patients and SIRS from patients with sepsis. 
PCT is a specificity marker for systemic bacterial infections but recent studies showed that plasma 
levels of PCT displayed no significative difference between infected and not infected patients. 
Therefore, in this case PCT plasma levels resulted not discriminant in PJI diagnosis. [5]
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2.1.3 Interleukin 6 (IL-6) 
Interleukin-6 is an endogenous chemical product that acts as both pro-inflammatory cytokine and 
anti-inflammatory myokine. 
Interleukin-6 (IL-6) is released by monocytes and macrophages in response to other inflammatory 
cytokines which include interleukin-11 (IL-11), and tumor necrosis factor-beta (TNF-β). 
IL-6 is involved in inflammatory condition during B cell maturation and it is secreted by T cells and 
macrophages to stimulate immune response. 
IL-6 is produced in the body in case of inflammation, either acute infection or chronic infection and 
interacts with interleukin-6 receptor alpha, to induce transcription of inflammatory gene products. 
The IL-6 receptor is present on normal T-lymphocytes cells in the resting phase, myeloid cells and 
hepatic cell line. [11] 
IL-6 has an important role in inflammatory processes, in particular in the acute phase response, in 
bone metabolism and in cancerogenesis processes. 
In PJI patients IL-6 can be used as biomarkers to discriminate between infected and non-infected 
patients, and recent evidences show that the levels of IL-6 can be higher than the normal range in 
patients who had a previous inflammation. [12]
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3.  New generation marker of infection  
In order to prevent prosthetic infection, aseptic surgical technique and antibiotics prophylaxis are 
used, but infection still occur in a quite relevant number of primary and revision arthroplasty. 
Treating prosthetic infections is very difficult, because pathogens that infect the site create biofilm 
on implanted material that hinders the leukocyte recruitment to the site of infection and the 
action of antibiotics. [13,14] 
Therefore, the early diagnosis of PJI still remains the best tool to promptly start the antibiotic 
treatment but a diagnostic gold standard is still lacking. [6,15] 
Our group investigated the diagnostic potential of new generation serum biomarkers for the 
diagnosis of PJI. In order to optimize the diagnostic process, infection biomarkers with fast 
response and high sensitivity and specificity for bacterial infection are needed. Biomarkers are 
defined as biological molecules that are characteristic of normal or pathogenic process and, 
therefore, they can be as useful in the clinical practice for the identification of the  pathological 
process and the monitoring of the disease progression [6,13] 
The ideal serum markers for PJI should be able to:  
• Have direct correlation with bone metabolism/infection, 
• Have more sensible to bone turnover alterations /infections, 
• Be less invasive on patients (blood), 
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• Consent regular, short interval monitoring 
Among this scenario, different molecules are emerging as potential biomarkers of PJI, as listed in 
the following sections.
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3.1 Soluble Urokinase Plasminogen Activation Receptor (suPAR) 
The first biomarker analyzed for the diagnosis of PJI is suPAR, the soluble urokinase plasminogen 
activation receptor, recently described as a powerful diagnostic and prognostic tool, able not only 
to detect sepsis but also to discriminate different grade of sepsis severity. 
The urokinase-type plasminogen activator receptor (uPAR) is a glycoprotein released during 
inflammation and infection. The soluble form of the receptor (suPAR) is obtained by proteolitic 
cleavage of uPAR from the cell surface and it is released in blood and other organic fluids such as 
plasma, urine, and cerebrospinal fluid. [16–18] 
suPAR is a biomarker of activation of the inflammatory and immune systems: suPAR levels are 
positively correlated with pro-inflammatory biomarkers, such as tumor necrosis factor-α, 
leukocyte counts, and C-reactive protein. Elevated levels of suPAR are associated with increased 
risk of systemic inflammatory response syndrome (SIRS). [19] 
SuPAR is a marker of disease severity and aggressiveness: high plasma suPAR levels have been 
described to be able to predict severity of disease outcome in various infection. [20,21] 
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3.2 TREM-1 
TREM-1 is a triggering receptor expressed on myeloid cells-1, and it is a member of the 
immunoglobulin superfamily. Its expression on phagocytes is upregulated by exposure to bacteria 
and fungi. 
The soluble form of TREM-1 (sTREM-1) can be found in body fluids, such as plasma, pleural fluid, 
Broncho alveolar lavage fluid, urine, and cerebrospinal fluid, where it can be assayed by using 
commercial immunoassay ELISA kits. [22,23] 
 
3.3 MMP-9 
Matrix metallopeptidase 9 (MMP-9) is a matrix of the class of enzymes that belong to the zinc-
metalloproteinase family involved in degradation of the extracellular matrix. 
MMP9 plays several important functions within neutrophil action, such as degrading extracellular 
matrix, activation of IL-1β, and cleavage of several chemokines. [24] 
 
3.4  CCL2 
Chemokine ligand 2 (CCL2) is also referred to as monocyte chemoattractant protein 1 (MCP1) and 
small inducible cytokine A2. 
CCL2 is primarily secreted by monocytes, macrophages and dendritic cells. To become activated 
CCL2 protein has to be cleaved by metalloproteinase MMP-12. [19] Once activated, CCL2 recruits 
monocytes, memory T cells, and dendritic cells to the sites of inflammation. 
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3.5 Osteopontin OPN 
Osteopontin (OPN) is a multifunctional glycoprotein with pro-inflammatory properties and it is 
correlated with SuPAR during inflammatory response. [25] 
In severe sepsis, OPN plasma level are significantly higher in non-survivors than in survivors. 
Recent studies indicated that OPN is associated with greater inflammatory response and increase 
mortality. [26,27] 
Therefore, we evaluated the level of OPN at following time point after surgery for infection 
eradication in order to analyze the diagnostic and prognostic potential of this marker in PJI, in 
comparison with Presepsin. 
 
3.6 Cluster of Differentiation 163 (CD163) 
Another emerging serum marker of infection is the hemoglobin (Hb) scavenger receptor, CD163. 
This is a macrophage-specific protein and the upregulated expression of this receptor is one of the 
major changes in the macrophage switch to alternative activated phenotypes in inflammation. 
Accordingly, a high expression in macrophages is a characteristic of tissues responding to 
inflammation. 
In addition to this biological role in inflammation, CD163 is a potential inflammation biomarker 
and a therapeutic target. The biomarker CD163 is the soluble plasmatic form sCD163 result from 
proteolitic cleavage of the membrane bound CD163, resulting into the shedding of CD163. [28,29] 
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3.7 TLR2 
Toll-like receptors (TLRs) are a class of proteins that play an important role in the innate immune 
response. They are single, membrane-spanning, non-catalytic receptors, usually expressed in 
sentinel cells such as macrophages and dendritic cells. TLRs receptor have the ability to recognize 
molecules that are broadly released by pathogens. [22] . In this way TLRs represent the first line of 
defense again invading pathogen, recognizing many bacterial, fungal and viral moecules. [30] 
When the TLR recognized the pathogen, it active the inflammatory response aimed to eliminate 
the pathogen and repair the damaged tissue.  
TLRs is expressed on antigen presenting cells (plasmacytoid dendritic cells, B cells, monocytes, and  
macrophages), T cells (activated CD4+, CD8+, memory, and T-reg), renal tubule epithelial cells,  
trophoblasts, and decidual and amnion epithelial cells. Soluble forms of TLRs retain ligand  
binding capability and function as decoy receptors that suppress TLRs mediated inflammation. 
TLR2 is one of the toll-like receptor and it plays an important role in the immune system.  
TLR2 is the most pleiotropic among the human TLR, as recognizes several components of Gram 
positive bacteria, such as peptidoglycan, the major component of Staphylococcus Aureus and 
other Gram positive bacteria, lipoteichoid acid, lipopeptides from Gram positive bacteria, as well 
as components of mycobacteria, fungi and yeast. [31] 
Since TLRs are responsible for the initial recognition of the pathogen and the engagement of the 
inflammatory response, they could provide useful information to the diagnosis of PJI. 
Indeed, the measurement of TLR expression has already been proposed in different inflammatory 
conditions, such as arthritis [30] and infection, ranging from skin [32] to bone infection. [5,33] 
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3.8 Presepsin  
One of the new emerging infection biomarkers is Presepsin, a fraction of the soluble form of CD14, 
recently described as a powerful diagnostic tool, able not only to detect sepsis but also to 
discriminate different grade of sepsis severity. [34] 
Cluster of differentiation 14 (known as CD14) is a glycoprotein expressed on the membrane 
surface of monocytes and macrophages and it binds lipopolysaccharides (LPSs) and LPS-binding 
proteins (LPBs). 
CD14 binds to lipopolysaccharide (LPS) complexes and LPS binding protein (LPB), which triggers 
activation of toll-like receptor 4 (TLR4), thereby inducing the production of several pro-
inflammatory cytokines. CD14 complex can also be released into the bloodstream as its soluble 
form (sCD14). 
sCD14 is in turn cleaved by a plasma protease to generate the sCD14 fragment sCD14-subtype 
(sCD14-ST) also called Presepsin. [35] 
Presepsin is a fraction of the soluble form of CD14, which is shedded from monocytes surface 
during inflammatory response and then released into blood.  
Plasma levels of Presepsin can be measured using an automated chemo luminescent assay. 
Therefore, Presepsin can be used a circulation marker of infection. sCD14 subtype (sCD14-ST), or 
Presepsin, is present in low concentrations in the plasma of healthy subject and it has been shown 
to be increased in response to bacterial infections. [34–36] 
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4 Aim of the PhD thesis 
 
The aim of this thesis was to investigate the potential diagnostic and prognostic value of Presepsin 
in the inflammatory response compared to other inflammatory mediators such as the chemokine 
CCL2 and the inflammatory cytokine, IL-6, in order to develop new diagnostic approaches for an 
integrated platform of point of care diagnosis of infection. 
The diagnostic and prognostic value of Presepsin on PIJ was also investigated correlating Presepsin 
values with other emerging infection markers such as TREM-1, CD-163 and SuPAR, OPN, TLR2 and 
MMP-9 which could be involved in the progression of PJI.  
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5 Methods 
Study population  
The population of 100 selected patients undergoing prosthesis revision was enrolled from IRCCS 
Istituto Ortopedico Galeazzi (Milan), IRCCS Istituto Ortopedico G Pini(Milan), and IRCCS Policilinco 
San Donato (Milan) and subdivided into two groups according to the cause of prosthesis implant 
failure: 
- 48 patients having bacterial infection (confirmed by positive culture test, with isolation of 
the causal agent in the infectious focus) 
- 52 patients with no infection, undergoing aseptic loosening of the implant. 
In the first group prosthetic infection was confirmed by clinical and laboratory data typical of bone 
joint infection: swelling, erythema, joint pain and secretion of purulent material, positive cultures, 
with isolation of the causal agent in the infectious focus.  
All procedures followed were in accordance with the 1975 Declaration of Helsinki, as revised in 
2000 and 2008.  Informed consent was obtained from all participants. The study approved by the 
local ethics committee (CE of IRCCS San Raffaele Hospital, Milan, CE/99/int/2015). Details that 
might disclose the identity of the subjects under the study were omitted, in accordance with 
HIPAA.  
Blood drawing was performed from all patients at different times points: 
- T0 (before surgery), 
- T1 (48 hours after surgery) 
- T2 (one month after surgery) 
- T3 (three months after surgery) 
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Blood was drawn from all patients for PLASMA + EDTA separation, liquored and stored at -80°C 
until further analysis. 
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Biomarkers evaluation 
CRP was measured using immunoturbidimetry on an automated biochemical analyzer (Olympus 
CRP-Latex assay, Central Valley, PA, CA, USA) 
IL-6, TREM-1, CCL2, MMP-9, OPN, TLR2 and CD163 were measured using an ELISA sandwich 
Quantikine Assay, according to manufacturer protocol (R&D System, Minneapolis, MN, USA) 
SuPAR was measured by Suparnostic ELISA Assay, according to manufacturer protocol (Virogates, 
Denmark)  
Presepsin levels was measured by Presepsin/ PATHFAST Immunoassay (Mitsubishi Chemical). 
PATHFAST is a compact immunoanalyzer analysis system for laboratories, hospitals and medical 
offices available wherever fast quantitative results (with full-scale lab quality) are required. 
PATHFAST Presepsin is a chemiluminescent enzyme immunoassay (CLEIA) for the quantitative 
measurement of Presepsin concentration. Monoclonal antibodies and polyclonal antibodies 
recognizing Presepsin are used in the assay. Using the PATHFAST analyzer Presepsin concentration 
can be determined within 17 minutes in six samples simultaneously. 
The test principle is based on non-competitive CLEIA combined with MAGTRATION technology 
(MAGTRATION is technology of bound/free (B/F) separation where magnetic particles are washed 
in pipette tip).  
Magnetic particles were coated by anti Presepsin polyclonal antibody and monoclonal antibody. 
During incubation with plasma, they form immunocomplexes with Presepsin present in the 
sample. 
After incubation the PATHFAST transfer sample immunocomplex, with anti Presepsin polyclonal 
and monoclonal antibody coated on magnetic particles bounded whit presepsin present in the 
sample, in the new well. 
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A chemiluminescent substrate (CDP-Star Chemiluminescent Substrate1) is added. After a short 
incubation, the luminescence intensity generated by the enzyme reaction is measured. The 
luminescence intensity is directly correlated to Presepsin concentration in the sample which is 
calculated by means of the standard curve. 
 
Statistical analysis 
For all the parameters analyzed, normality of distribution of the groups was verified by KS 
normality. 
Statistical analysis was performed using One-way ANOVA test, p< 0.05 was considered significant 
and p< 0.005 very significant. Data are expressed as the mean ±standard deviation (SD). 
Correlation analysis was measured using PRISM 3.0 software, by performing linear regression 
analysis between the different groups of data and calculating the 95% confidence interval of the 
regression line.  
The Pearson correlation coefficient (r2) was calculated to determine correlation between values 
measured by the different assays. The Mann–Whitney test was used for comparing values from 
patients and donors 
Statistical analysis of Receiver Operating Characteristic (ROC) curves and Area Under the Curve 
(AUC) was performed by MedCalc 13.2.2 Software, (Ostend, Belgium) 
                                                          
1 Disodium 2-chloro-5-(4-methoxyspiro[1,2-dioxetane-3,2′-(5-chlorotricyclo[3.3.1.13.7]decan])-4-yl]-1-phenyl 
phosphate 
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6 Results  
In the first part on my PhD project, the two biomarkers sTLR2 and suPAR were evaluated in the 
diagnosis of prosthetic joint infection. 
They were subsequently compared to Presepsin, as well as other new generation inflammatory 
markers, in the prognostic evaluation of prosthetic joint infection. 
 
 
6.1 Toll-like receptor 2 in serum: a potential diagnostic marker of prosthetic joint 
infection? 
Galliera E, Drago L, Vassena C, Romanò C, Gioia Marazzi M, Salcito L, Corsi Romanelli MM. J Clin 
Microbiol. 2014 Feb;52(2):620-3. doi: 10.1128/JCM.02727-13. 
 
 
The interplay between the immune system and bone metabolism has been recognized as 
important for both of these systems. Toll-like receptors (TLRs) are a class of proteins that play an 
important role in the innate immune response activating the inflammatory reactions. 
TLR2 and TLR4 are also expressed in bone cells, and their activation affects osteoclasts 
differentiation and activity. Moreover, in osteoblasts TLRs induce the production of 
osteoclastogenic cytokines (RANKL and TNF-α), thereby contributing to TLR ligand-induced 
osteoclastogenesis. 
These processes are involved in bone loss observed in variety of infectious diseases. Various 
factors produced and released during immune responses markedly affect bone cells and bone 
metabolism.  
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Implant infection is a severe complication requiring implant replacement. For example, in bone 
osteolysis the local bone loss is due to the inflammation in response to pathogen infection. 
Prosthetic joint infection (PJI) is a major problem in patients undergoing athroplasty, but since the 
clinical presentations are variable and the efficacy of diagnostic approaches are low, there is still 
need to improve diagnostic methods. PJI is mainly due to Staphylococcus Aureus, a Gram positive 
bacterium recognized by TLR2, and more rarely by Gram negative bacteria such as Pseudomonas, 
recognized by TLR4. 
In order to evaluate the potential diagnostic role of TLR2 and TLR4 in PJI, in this study TLR2 and 
TLR4 serum levels, as well as inflammatory marker (IL-6, TNF-α and IL-1, PCR) were evaluated in 32 
selected patients undergoing revision of total hip or total knee joint arthroplasty and displaying 
prosthetic chronic infection for at least 6 months, as demonstrated by clinical and laboratory signs 
typical of bone joint infection: swelling, erythema, joint pain, and secretion of purulent material . 
As a control group, we selected 28 non infected patients undergoing routine orthopedic surgery 
without any other underlying disease or infection of inflammation and showing no comorbid 
conditions that could affect the expression of TLR2 and other markers, as well as no antibiotic 
therapy in progress, and no diabetes mellitus type 2 or obesity. 
While TLR4 displayed no significative differences, TLR2 level resulted higher in septic patients and 
correlated with IL-6 and PCR levels. Accordingly, IL-1beta, the main TLR2 co-player of the 
inflammatory response to Staphylococcus Aureus, resulted higher in septic patients.  
These results indicated that TLR2 play an important role in the inflammatory response to 
prosthetic join infection. Therefore, the measure of TLR2 serum level could be considered a 
potential diagnostic tool that could be used in association with canonical inflammatory 
parameters for the early detection and diagnosis of prosthetic join infection. 
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6.2 Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker 
of the prosthetic joint infection: correlation with inflammatory cytokines. 
Galliera E, Drago L, Marazzi MG, Romanò C, Vassena C, Corsi Romanelli MM. 
Clin Chim Acta. 2015 Feb 20; 441:23-8. doi: 10.1016/j.cca.2014.11.029. 
 
There is a universally recognized need to identify new, reliable markers of inflammation that can 
aid in the rapid diagnosis of orthopaedic joint prosthesis infections (PJI). PJI is the most common 
cause of failure of total joint arthroplasty, requiring revision surgery, but a gold standard for the 
diagnosis and the treatment of PIJ is still lacking. 
PJI is mainly due to Staphylococcus Aureus, a Gram positive bacterium and more rarely by Gram 
negative bacteria such as Pseudomonas. 
This study aimed examine the diagnostic value of SuPAR in post-operative prosthetic joint 
infection, in order to explore the possible application of this new biomarker in the early diagnosis 
of PJI. 
The urokinase-type plasminogen activator receptor (uPAR) is a glycoprotein released during 
inflammation and infection. The soluble form of the receptor (suPAR) is obtained by proteolitic 
cleavage of uPAR from the cell surface and it is released in blood and other organic fluids such as 
plasma, urine, and cerebrospinal fluid.  
In this study, a population of 60 selected patients was enrolled and subdivided into two groups: 32 
patients having bacterial infection (confirmed by positive culture test, with isolation of the causal 
agent in the infectious focus) and control group of 28 not septic patients, undergoing orthopedic 
surgery, in order to explore the possible application of this new biomarker in the early diagnosis of 
PJI. The level of SuPAR has been determined using commercial double monoclonal antibody 
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sandwich immunoassay and correlated with canonical inflammatory markers, such as C-reactive 
protein, IL-6, IL-1 and TNFα and the chemokine CCL2 measured in the two groups of patients. 
Serum suPAR level displayed a strongly significative increase in PJI patients compared to not 
infected controls, and a significative positive correlation with C-reactive protein, IL-6, IL-1, TNFα. 
Also serum level of CCL2 showed a statistically significative increase in PJI patients and it displayed 
a strong positive correlation with serum suPAR. Moreover, the ROC analysis and AUC indicated a 
good diagnostic potential of suPAR in PJI determination. 
This study provides a clear indication of the diagnostic potential of suPAR, in association to routine 
inflammatory parameters, such as CRP and IL-6, in the diagnosis of Prosthetic joint infection.  
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6.3  Evaluation of diagnostic values of Presepsin in PJI 
 
Presepsin resulted significantly higher in PJI patients compared to controls. In particular, Presepsin 
in PJI was583,7 ± 250,64 pg/ml, while in not infected patients resulted 196,54 ± 141,68 pg/ml, with 
a very highly statistically significance (p<0.001, FIGURE 1 PANEL A). In order to compare the 
diagnostic value of Presepsin with inflammatory markers currently used in the clinical detection of 
PJI, we measured C-Reactive Protein and IL-6. 
CRP displayed a statistically significative increase (p<0.001, FIGURE 1 PANEL B) in PJI patients 
(2.63±1.79 mg/dL), compared to controls (0.5±0.2 mg/dL). Even considering this increase, CRP 
value display a little increase compared to the cut off value of 1 mg/dL, therefore the single 
evaluation of CRP cannot be considered clinically determinant for PJI diagnosis. 
IL-6 displays a significative increase p<0.001 in PJI patients (11.12 ±2.36 pg/mL) compared to not 
infected patients (1.81 ±0.85 pg/mL), FIGURE 1 PANEL C), confirming the ongoing inflammatory 
response in PJI patients 
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In Figure 2 Presepsin shoes a very good positive linear correlation with both the inflammatory 
markers analyzed (r2=0.862 and r2=0.887 with CRP and IL-6, respectively), confirming its value as a 
marker of the inflammatory process in response to the infection. 
In order to clearly compare the clinical diagnostic value of Presepsin with the two currently 
inflammatory markers currently used in PJI diagnosis, we calculated the ROC curve for Presepsin, 
IL-6 and CRP. (FIGURE 3) 
The ROC curves can evaluate the diagnostic efficacy of a diagnostic test, by measuring the area 
under the ROC curve (AUC). In the clinical practice a diagnostic test is considered acceptable if its 
AUC is ≥ 0.8 
In our patients AUC resulted:  
 
- CRP, AUC = 0.750, very low diagnostic efficacy (FIGURE 3 - PANEL A), 
- IL-6, AUC = 0.821, minimal diagnostic efficacy (FIGURE 3 - PANEL B), 
- Presepsin, AUC= 0.926, very good diagnostic efficacy (FIGURE 3 - PANEL C). 
 
These results clearly indicated that Presepsin has a greater diagnostic value that CRP and IL-6 in 
the diagnosis of PJI, and therefore it can be considered a better diagnostic marker that could be 
introduced in the clinic for the detection of PJI. 
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6.4 Evaluation of prognostic values of Presepsin in PJI 
Figure 4 
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Once evaluated the diagnostic value of Presepsin in the clinical detection of PJI, we wanted to go 
further in the analysis of this molecule by evaluating whether Presepsin could have also a 
prognostic value in the clinical monitoring of the follow up of PJI after the revision surgery. 
For this reason, in the second part of my PhD thesis we performed a longitudinal study by 
analyzing Presepsin serum values at different time points after revision surgery, both in PJI 
patients and in aseptic loosening of the implant (not infected subject, control group). 
In figure 4 Presepsin displays a significant decrease at the increasing time of recovery after surgery 
in PJI patients (FIGURE 4 PANEL A), while it remains unaltered and significantly lower (p<0.0001, 
FIGURE 4 PANEL B) in the patients undergone to revision surgery for aseptic loosening of the 
implant. 
In order to complete the evaluation of Presepsin in the clinical diagnosis and monitoring of PJI, we 
compared Presepsin serum level with other markers of infection and inflammation, such as the 
chemokine CCL2, the new emerging markers of infection OPN (osteopontin), TLR2, CD-163, TREM-
1 and SuPAR in the same longitudinal study. 
First of all, the diagnostic value of all these markers have been evaluated by ROC AUC analysis 
(FIGURE 5). 
OPN, CCL2, SuPAR and TLR2 displayed good diagnostic values in PJI, having AUC values of: 
- OPN, AUC = 0.859, (FIGURE 5 - PANEL A), 
- CCL2, AUC = 0.868, (FIGURE 5 - PANEL B), 
- SuPAR, AUC = 0.866, (FIGURE 5 - PANEL F) respectively, 
- TLR2, AUC = 0.898, (FIGURE 5 - PANEL G) respectively. 
while CD163, TREM-1 and MMP-9 displayed very low diagnostic potential, showing AUC values of: 
- CD163, AUC = 0.776, (FIGURE 5 - PANEL C), 
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- TREM-1, AUC = 0.751, (FIGURE 5 - PANEL D), 
- MMP-9, AUC = 0.597, (FIGURE 5 - PANEL E) respectively.  
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In the longitudinal study, in order to evaluate the progressive resolution of the inflammatory 
process, we analyzed the primary inflammatory cytokine, IL-6. 
IL-6, which is also currently used a diagnostic tool for the clinical evaluation of PJI, in FIGURE 6 IL-6 
serum level is higher in PJI patients (16.58 ± 4.37 pg/mL) and displayed a gradual decrease as long 
as the recovery time after surgery (p<0.0001), while in not infected patients Il-6 resulted 
undetectable at all the time points analyzed. 
Since Presepsin, the soluble form of CD14 ligand, originates from mononuclear cells, we evaluated, 
in parallel with Presepsin, the main monocytes attractant chemokine, CCL2 (FIGURE 7). 
As expected, the serum level of CCL2 is higher in PJI patients (318.58 ± 86.23 pg/mL) compared to 
control group with aseptic loosening of the implants (162.48 ± 48.21 pg/mL). At following time 
points, the level of the chemokine decrease rapidly, similarly to Presepsin.  
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Besides, OPN displays a significative increase in infected patient (179,71 ± 56.11 pg/mL) compared 
to not infected one (46.18 ± 18.02 pg/mL, FIGURE 8). In addition, OPN showed the same gradual 
decrease observed for Presepsin, even if a significative standard deviation is observed at T0 and 
T1. 
 
 
 
 
Figure 8 
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We also extend the analysis of inflammatory marker to other emerging molecules in the diagnosis 
of infection, such as CD163 and TREM-1. 
In FIGURE 9 CD163 displayed a gradual decrease at following time points, but it showed no 
significative difference between infected (626.28 ± 18.02 pg/mL) and not infected patients (426.8 
± 16.23 pg/mL). This result indicates that CD163 cannot be considered a good marker for PJI 
infection. 
 
 
 
 
Figure 9 
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TREM-1, in FIGURE 10 displayed a significative decrease in T1 and following time points, reaching 
comparable value to not infected patients. 
However, the absolute value of serum TREM-1, event in the highest level of T0 (17.07 ± 5.01 
pg/mL), is far below the diagnostic cut off of 30 pg/mL reported in literature. 
 
 
 
Similarly, to TREM-1, the level of MMP9 at T0 was very low (12.77 ± 4.22 ng/mL) compared to 
diagnostic cut off levels, FIGURE 11  
 
 
Figure 10 
Figure 11 
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On the contrary, the inflammatory marker SuPAR (FIGURE 12), previously described as having a 
diagnostic potential role in PJI [20], displayed the same gradual decrease observed for Presepsin. 
SuPAR resulted significantly higher in PJI patients compared to controls. In particular, SuPAR in PJI 
was 9.27 ± 2.78 pg/ml, while in not infected patients resulted 3.12 ± 1.00 pg/ml, with a very highly 
statistically significance (p<0.001). 
 
 
 
Figure 12 
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Figure 13 
 
Since the Prosthetic joint infection in mainly due to Gram positive bacteria, we evaluated the 
Gram positive specific Toll Like receptor TLR2.  
TLR2, previously described as having a diagnostic potential in diagnosis of PJI and in particular 
confirming a Gram positive infection, displayed the same gradual decrease observed for Presepsin. 
TLR2 resulted significantly higher in PJI patients compared to controls. In particular, TLR2 in PJI 
was 6.68 ± 3.13 ng/ml, while in not infected patients resulted 1.73 ± 0.88 ng/ml, with a very highly 
statistically significance (p<0.001). At T1 the decrease of serum TLR2is not statistically significative, 
while at following time points T2 and T3 it reaches values comparable to not infected patients. 
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7. Discussion  
Pathogen infection is one of the main adverse events of surgical procedures, which can lead to an 
excess of systemic inflammatory response and sepsis, causing multi organ failure and septic shock. 
[37,38] 
In the orthopedic field, the periprosthetic joint infection is a particularly challenging complication 
associated with surgical procedures, especially hip and knee arthroplasty.[39] 
The most common cause of failure of total joint arthroplasty is PIJ, and it even requires revision 
surgery.[40] 
The principal cause of PIJ are Gram positive bacterial infection: the most of the time 
Staphylococcus Aureus, and more rarely Gram negative bacteria such as Pseudomonas. [41] 
At the moment many tests are available for PIJ diagnosis, many of which can be used in 
combination. 
Ranging from haematological markers of infection and inflammation, intraoperative culture, 
histology analysis. [1,3,42] 
Nevertheless, there is not yet a gold standard for the diagnosis, consequently, for the treatment of 
PIJ. [43] 
The clinical presentation is often ambiguous [40,44] and although classical inflammatory markers 
like C-reactive protein are helpful, they can be misleading in some cases, such as patients with 
chronic disease, post-operative hematomas, obesity, metabolic syndrome and insulin resistance 
and smokers. [45] 
Infection biomarkers with fast response, high sensitivity and specificity for infection are essential 
for the optimization of the diagnostic process. 
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Biomarkers can be useful indicators for the clinical practice, since they are biological molecules 
that are characteristic of “normal” or “pathogenic process”. [46,47] 
In this context, a previous study of our group investigated the role of Procalcitonin, C reactive 
protein and Il-6 as markers of post-operative orthopedics joint prosthesis infection, indicating that 
IL-6 and CRP were useful in the differentiation between patient with or without post-operative PIJ, 
while C reactive protein had not a great diagnostic value in this case. [5] 
Therefore, there is still the need to improve the diagnostic tools for the early detection of PJI and 
new emerging infection biomarkers were identified as inflammatory molecules involved in host 
response to bacteria, such as Toll like receptors. 
Among innate immunity mediators, Toll-like receptors (TLRs) plays a crucial role in inflammation 
because they sense pathogen-derived molecules and initiate the inflammatory response. TLRs are 
also expressed in bone cells, and their activation affects osteoclasts differentiation and activity. 
A recent study of our group evaluated the potential diagnostic role of TLR2 and TLR4 in the early 
detection of Prosthetic joint infection (PJI). 
In septic patients TLR2 level is higher and correlates with inflammatory markers (IL-6 and C 
reactive protein), while TLR4 display no significative differences. [31] 
Accordingly, IL-1beta, the main TLR2 co-player of the inflammatory response to Aureus, is higher 
in septic patients than in not septic patients. These results strongly suggested that TLR2 is 
essential in the inflammatory response to pathogen induced prosthetic join infection. 
Thus, the measure of TLR2 circulating level could be very informative in the early detection of PJI 
and, therefore, it could be considered potential diagnostic tool that could be associated with 
canonical clinical markers of inflammation in order to improve the diagnosis of prosthetic joint 
infection. [22,48,49] 
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An important role inflammatory response mediated by monocytes/ macrophages against invading 
bacteria, is played by SuPAR, the soluble urokinase plasminogen activating receptor. 
The urokinase-type plasminogen activator receptor (uPAR) is a glycoprotein released during 
inflammation and infection, thereby promote the migration and adhesion of leukocytes. The 
soluble form of the receptor (suPAR) is obtained by proteolitic cleavage of uPAR from the cell 
surface, therefore suPAR can be found in blood and other organic fluids. [25] 
High plasma levels of suPAR have been described to be able to predict severity of disease outcome 
in various infections. SuPAR could find new fields of diagnostic application, where a clear detection 
of the infection is still lacking, such as prosthesis joint infection. As shown paper (SUPAR), resulted 
clearly higher in PJI patients compared to not infected patients and showed a good positive 
correlation with CRP and other inflammatory markers. The measure of Serum level of SuPAR 
provide an extremely important benefit because it is a precise indicator of bacterial infection, and 
the addition of SuPAR serum level measurement to classical inflammatory markers can strongly 
improve the diagnosis of prosthesis joint infection. [17,19,50,51] 
Among the scenario of infections diagnosis, an emerging molecule is Presepsin, the soluble 
fraction of CD14, recently described as a powerful diagnostic tool, able not only to detect sepsis 
but also to discriminate different grade of sepsis severity. [35,36] 
Presepsin is a fraction of the soluble form of CD14, which is shedded from monocytes surface 
during inflammatory response and then released into blood. Therefore, Presepsin can be used a 
circulation marker of infection, but so far little is known about the mechanism of this sCD14 
fraction shedding. A better understanding the mechanism of action of Presepsin in the 
inflammatory response, and its correlation with other inflammatory mediators could improve the 
diagnostic potential and clinical application of Presepsin. [38,48] 
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To this purpose Presepsin was compared to the two infection marker previously described (TLR2 
and SuPAR) as well as new generation infection marker such as TREM-1, CD-163, OPN. 
 In order to confirm the ongoing inflammatory response, the IL-6 serum level was evaluated in PJI 
and not infected patients, as well as the chemokine CCL2, the main mediator of monocyte 
recruitment. 
IL-6 display a significative increase, confirming the ongoing inflammatory response in PJI patients. 
Presepsin resulted significantly higher in PJI patients compared to not infected controls. Moreover, 
Presepsin has a greater diagnostic value that CRP and IL-6 in the diagnosis of PJI. Therefore, it can 
be considered a better diagnostic marker that could be introduced in the clinic for the detection of 
PJI. 
Once evaluated the diagnostic value of Presepsin in the clinical detection of PJI, we wanted to go 
further in the analysis of this molecule by evaluating whether Presepsin could have also a 
prognostic value in the clinical monitoring of the follow up of PJI after the revision surgery. 
For this reason, in the second part of the project we performed a longitudinal study by analyzing 
Presepsin serum values at different time points after revision surgery, both in PJI patients and in 
aseptic loosening of the implant (not infected control group). 
Presepsin displays a significant decrease at the increasing time of recovery after surgery in PJI 
patients, while it remains unaltered and significantly lower (p<0.0001) in the patients undergone 
to revision surgery for aseptic loosening of the implant. 
These results clearly indicate that Presepsin is not only a useful diagnostic tool in the diagnosis of 
PJI, but is also have a prognostic value, because its decrease gradually as the inflammatory process 
in response to the prosthetic infection is resolved. 
At the first time point analyzed (T1, one week after surgery) Presepsin is nearly 50% of the value a 
T0, but it does not reach the value of not infected patients: this is probably due to the clearance 
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time of the molecule from the circulation in the early time point after surgery.  At following time 
points after surgery, which eradicates the infection, Presepsin values in PJI patients are 
comparable with the ones of not infected patients. These results are crucial in the follow up of 
prosthetic surgery revision, because the incidence of a second infection is not low and it would 
lead, if not detected early, to a second revision surgery. 
For this reason, a marker like Presepsin could be introduced not only in the follow up of PJI 
patients after the prosthetic revision surgery, in order to early detect any possible second 
infection, but, more interestingly, in the routine follow up after the first prosthetic surgery, in 
order to early detect any possible prosthetic infection at the first time. 
This would allow a prompt therapeutical (antibiotic) intervention in order to avoid the revision 
surgery, which has more impact on the patient.  
In order to complete the evaluation of Presepsin in the clinical diagnosis and monitoring of PJI, we 
compared Presepsin serum level with other markers of infection and inflammation, such as the 
chemokine CCL2, the new emerging markers of infection OPN (osteopontin), CD-163, TREM-1 and 
SuPAR, TREM-1, in the same longitudinal study. [50,52] 
OPN, CCL2 and SuPAR displayed good diagnostic values in PJI, having AUC values 0.859, 0.868 and 
0.866 respectively while CD163, TREM-1 and MMP-9 displayed very low diagnostic potential, 
showing AUC values of 0.776, 0.751 and 0.597 respectively. These results indicate that, among the 
inflammatory markers analyzed, the most relevant for PJI diagnosis are the one related to 
monocyte/macrophage mediated inflammatory response, such as the monocyte specific 
chemokine CCL2, SuPAR and OPN. In the longitudinal study in order to evaluate the progressive 
resolution of the inflammatory process, we analyzed the primary inflammatory cytokine IL-6, 
which is also currently used a diagnostic tool for the clinical evaluation of PJI.  
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IL-6 displayed a gradual decrease as long as the recovery time after surgery, while in not infected 
patients Il-6 resulted undetectable at all the time points analyzed. 
On the one hand this results confirm the difference between the inflammatory response elicited 
by the Prosthetic infection and the aseptic loosening of the implant. On the other hand, this result 
is in accordance with Presepsin decrease during recovery after surgery, confirming the potential of 
Presepsin as a marker of infection and, in this case, of the resolution of infection. 
Since Presepsin, the soluble form of CD14 ligand, originates from mononuclear cells, we evaluated, 
in parallel with Presepsin, the main monocytes attractant chemokine, CCL2 (Figure 6). 
As expected, the serum level of CCL2 is higher in PJI patients (318.58 ± 86.23 pg/mL) compared to 
control group with aseptic loosening of the implants (162.48 ± 48.21 pg/mL). 
At following time points, the level of the chemokine decrease rapidly, similarly to Presepsin.  
CCL2 is the main chemokine regulating monocyte and macrophage activity, therefore this results 
are accordance with recent evidences indicating that Presepsin is released upon macrophage 
phagocytosis.  
SuPAR, previously described as having a diagnostic potential role in PJ, displayed the same gradual 
decrease observed for Presepsin, confirming the potential role of Presepsin in the prognostic 
evaluation of PJI. 
A strong correlation has been described between CD14 and Toll like receptor, in particular TLR2 
and TLR4. [19,48,53] 
We have previously shown that TLR2 display a good diagnostic potential in PJI, confirmed by a AUC 
of 0.898, therefore we evaluated TLR2 in the longitudinal study. TLR2 display a little decrease at 
the first time point of 48h, while at following time points it reaches values comparable to not 
infected patients. 
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These results indicate that it cannot be considered not an early marker of eradication of infection, 
but at the later time points it follows the same trend of decrease of Presepsin. 
Osteopontin (OPN) is a multifunctional glycoprotein with pro-inflammatory properties. In severe 
sepsis, levels of plasma OPN are significantly higher in non-survivors than in survivors. [25] 
Recent studies indicated that OPN is associated with greater inflammatory response and increased 
mortality, therefore we evaluated the level of OPN at following time point after surgery for 
infection eradication in order to analyze the prognostic potential of this marker in PJI and compare 
it to Presepsin. [26] 
CD163 displayed a gradual decrease at following time points, but it showed no significative 
difference between infected This result indicates that CD163 cannot be considered a good marker 
for PJI infection. This results reflect the specificity of PJI infection, where not all the infection 
markers, such as the canonical C-reactive protein, resulted sufficient to detect the infection. In the 
case of CD163, this marker is mainly reported to be a good marker the case on viral infection and 
chronic inflammation. [54] 
Therefore, this can be the reason why it resulted not significant in the case of PJI, but the weak 
increase at T0 can be due only to the inflammatory response in PJI patients. 
A connection between Toll like receptors, monocytes, inflammatory cytokines such as IL-1 and IL-6 
and the chemokine CCL2, in the mechanism of action of Presepsin could be represented by the 
new infection marker TREM-1. [55] 
TREM-1 is related to different aspects of the inflammatory response: TREM-1 is involved in TLR 
signaling, acting as an “amplifier of inflammatory response”, it is over-expressed on monocytes in 
parallel with CD14 in septic condition, then it is shedded from monocytes by the action of the 
metalloprotease MMP-9 and then it induces the inflammatory cytokines IL-1, IL-6, TNF-alpha and 
CCL2. In Prosthetic Joint infection other canonical infection makers, such as the C-Reactive Protein, 
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resulted below the diagnostic cut off limit, and this account for the difficulties in the early 
detection of the infection and the need of alternative diagnostic markers. In this case, TREM-1 
cannot be considered a useful tool for the diagnosis and prognosis of Prosthetic joint infection. 
Since the soluble form of TREM-1 is released through the action of MMP-9, we evaluated the level 
of MMP-9 at the same time points of TREM-1. 
No significative differences was observed between PJI patients and controls at any time points, 
confirming that the axis MMP-9 /TREM-1 is not involved Prosthetic Joint infection. 
Limitations of our study are the number of infected patients, but this is consistent with the very 
low frequency of Prosthetic Joint infection, which occurs in the 2.18% for hip arthroplasty and to 
2.18% for knee arthroplasty [56] 
To overcome this limitation, we enrolled PJI patients from different orthopedic institutes  
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8. Conclusion 
Taken together, these results indicate that Presepsin can be considered a useful tool for the 
diagnosis and clinical monitoring of prosthetic joint infection, and it can also be supported by a 
panel of new inflammatory makers involved in monocyte/macrophage mediated inflammatory 
response such as OPN, CCL2 and SuPAR. 
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